Vera Therapeutics, Inc. (VERA) Stock Score, Valuation & Financial Research

Vera Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VERA

Vera Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 30.42. These figures are a research snapshot, not a buy or sell recommendation.

What Vera Therapeutics, Inc. does

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with immunological diseases. The company currently operates as a research and development entity and has not yet generated revenue from product sales, relying instead on capital raises and strategic collaborations to fund its operations.

Products and services

  • The company's primary product candidate is atacicept, a fusion protein targeting BAFF and APRIL for the treatment of IgA nephropathy and other autoimmune diseases. It is also developing VT-109, a next-generation fusion protein for B-cell-mediated diseases.

Brands and product families

  • Atacicept — Lead clinical-stage product candidate for IgA nephropathy. Source
  • VT-109 — Preclinical-stage fusion protein candidate. Source

Customer types

Healthcare providers and patients with immunological diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Stanford University — A license agreement to acquire global rights to VT-109, a novel fusion protein targeting BAFF and APRIL for B-cell-mediated diseases. Source

Competitors and product-market comparisons

  • RemeGen — Developer of telitacicept, a biologic fusion protein that competes in the space of B-cell-mediated disease therapeutics. Source

Business strengths to evaluate

  • Clinical progress of atacicept in IgA nephropathy Source

Business risks and research considerations

  • Dependence on third-party manufacturers and clinical trial success Source
  • History of operating losses and potential need for additional capital Source

Sources: Company research source · RemeGen

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VERA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 30.42
Market capitalization:
2.18B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -401.9M
Free cash flow:
USD -241.73M
Cash:
USD 48.88M
Total debt:
USD 75.23M
EPS:
USD -5.86

What stands out

  • Free cash flow is USD -241.73M, negative for the stored period.
  • The balance sheet shows USD 48.88M of cash versus USD 75.23M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 26.35M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VERA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VERA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does VERA's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for VERA to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of VERA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research VERA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.